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Summary: Purified antibodies to human serum albumin or to human γ-globulin were used to study the direct
influence of some antirheumatic drugs on the formation and disruption of immunoprecipitates. 125I-labelled human
serum albumin and 125I-labelled human IgG served as indicators. The effects of the following drugs were described:
diclofenac, monophenylbutazone, diphenylbutazone, ibuprofen, and metamizol. At approximately therapeutic con-
centrations, the antirheumatics inhibited the formation of complexes of homologous antibodies with human serum
albumin and, surprisingly, with human IgG. When the antigens were precipitated with antibodies, subsequent addi-
tion of the antirheumatics to the preformed immunoprecipitates caused disruption of [125I]human serum albumin-
anti-human serum albumin precipitates but practically no disruption of human [125I]IgG-anti-human IgG precipi-
tates. These new findings may be of relevance for clinical diagnosis and therapy as well as for research in immuno-
chemistry. It is conceivable that, in patients, antirheumatic or other drugs might interfere with immunological
determinations of climcorchemical quantities. Interference of drugs with antigen-antibody reactions might also help
to explain some beneficial effects or undesirable side effects of certain drugs.
Introduction Materials and Methods
Using a special radioimmunological technique (1) for Preparation of antibodies
experiments on the dye-binding capacity of traces of Female rabbits weighing 3-4 kg were hyperimmunized to either
human serum albumin in a case of Bennhold's analbu- 5™ se[um,albumin (hi*h TJW?1 B^n^r\e'Marbu^Germany) or human serum γ-globulm (Benglobm®, Behnngwerke,
mmaemia (2, 3) and in normal subjects, it was inci- Marburg/Germany) using, in principle, a method described pre-
dentally observed that bromophenol blue, in amounts viously (1). The rabbits received, partly iv and partly sc, increasing
exceeding 15-20 mol per mol human serum albumin, fses of either human serum albumin or human IgG every second0 * ' day, starting from 7mg and increasing to 42 mg within 23 days;
could release increasing amounts of 12:>I-labelled hu- iomg were administered on the 25th day, and the rabbits were
man serum albumin from albumin-anti-alb min immu- bled on the 27th or 28th day.
noprecipitates. At extremely high bromophenol blue the rabbit IgG was obtained by fractional precipitation
concentrations, the precipitates were practically com- with ammonium sulphate, descending from 40 percent to 35
pletdy dis,o,ved. Amonic antirheumatte, analgetic and ϊ^^ϊΤίΤ'ΑΑΓΟΑΑ' £
antipyretic drugs and other substances, some of which many). The ethacridin was removed with 0.85 mol/1 (50 g/1)
are known for their competitive properties (4-7), were NaCl. After dialysis of the supernatant against phosphate-
therefore tested in this syseem. These drugs were con,- «f- -*£ *£** ΓΡ±Α± 5£
pared with other substances selected at random. saturation, then dissolved in water, dialysed against 1 :9 diluted
phosphate-buffered saline» and finally lyophilized. The dried rab-
bit IgG was dissolved in water to give 10—20 g/1 rabbit IgG so-
lutions.
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125I-labelled human serum albumin was obtained from Amers-
ham/Buchler (Braunschweig, Germany). Highly purified human
IgG (Behringwerke, Marburg, Germany) was labelled according
to the method of Hunter & Greenwood (10). For radioiodination
of 20 μg of human IgG in 1.5 ml phosphate-buffered saline,
25.5 MBq 125I and 0.5 mg chloramine-T were used.
Inhibi t ion and disruption experiments
In general, stock solutions (from commercial ampules or from
preparations of pure substances) of the drugs were diluted 1 : 30
(or in some cases, 1 : 25,1 : 100, 1 : 1000, and 1 : 2000) with phos-
phate-buffered saline. Almost all experiments were run in tripli-
cate, a few others in duplicate.
For determination of the antigen-antibody titre, constant volumes
of 100 μΐ of the antibody solutions were mixed with different vol-
umes of the corresponding 125I-labelled antigen solution. The opti-
mal antigen volume was read from the resulting Heidelberger pre-
cipitin curve. Immunoprecipitates with relatively loose antigen-an-
tibody bonds were prepared by precipitation in the slight antigen
excess region, i. e. at points between 80% and 45% antigen precipi-
tation. To facilitate resuspension, the immunoprecipitates were fro-
zen in phosphate-buffered saline at -20 °C and thawed before
washing.
In the inhibition experiments using the anti-human serum albumin
antibody #2/93, 10 μΐ 125I-labelled human serum albumin solution
\vere mixed with 25 μΐ drug solution, then left for 15 min at room
temperature. Subsequently 50 μΐ anti-human serum albumin #2/93
were added, and the tubes incubated for 15 min at 37 °C and left
to stand > l h at 8 °C.
For the controls, 25 μΐ phosphate-buffered saline were substituted
for the 25 μΐ drug solution. All preparations were made up with
phosphate-buffered saline pH 7.4 to a final volume of 200 μΐ and
the total radioactivity was measured in a Multigamma® counter
(LKB, Turku/Finland). After centrifugation at 3000 g and removal
of the supernatant with a pipette, the samples were again washed
and measured. For calculation, the radioactivity of the control pre-
cipitates was assigned a value of 100%.
For the disruption experiments, the immunoprecipitates were pre-
pared first and the washing-out effect caused by the solubility of
the immunocomplexes in phosphate-buffered saline was deter-
mined. The radioactivity of the washed precipitates was assigned
a value of 100% and these precipitates served as controls.
In orientation experiments, it turned out that the disruption of the
human serum albumin immunoprecipitates depended not only on
the actual concentration of the drugs but also on the volume of the
equimolar drug solution. After mixing 25 μΐ drug solution with
45 μΐ human serum albumin solution, 50 μΐ of antibody solution
#2/93 were added to each sample in the centrifuge tubes. The final
volume of the batches was then adjusted to 200 μΐ with phosphate-
buffered saline. Accordingly, the actual concentration of the drugs
was diluted 1 : 8 in the human serum albumin inhibition experi-
ments. In order to obtain measurable values in the disruption ex^
periments, however, 150 μΐ drug solution had to be added to each
preformed immunoprecipitate. Thereafter, the batches were also
made up with phosphate-buffered saline to a final volume of 200
μΐ, i. e. a dilution of only 3 :4. Hence, both the molar amount of
the drugs (mol drug/mol human serum albumin) and the actual
drug concentrations were much greater than in the inhibition ex-
periments.
Results
As figure la shows, some antirheumatic and analgetic
drugs such as metamizol, monophenylbutazone, diphe-
nylbutazone, diclofenac, and ibuprofen, at concentra-
tions down to the upper micromolar therapeutic range,
measurably inhibit the formation of human serum albu-
min-anti-human serum albumin precipitates at pH 7.4
in phosphate-buffered saline solution (NaCl, 51 mmol/1;
Na2HPO4, 167 mmol/1; KH2PO4, 67.5 mmol/1).• r
The inhibiting drugs also disrupt some immunoprecipi^
tates, though in general to a much lesser extent (fig.
Ib). The differences between inhibition of formation of
immunoprecipitates and disruption of preformed precip-
itates suggest that the drug-binding sites of human se-
rum albumin are only partly involved in the antigen-
antibody reaction. In addition, some drug-binding sites
of the human serum albumin are not obstructed by im-
muno-binding sites of the homologous antibody. In the
disruption experiments, the preformed immunoprecipi-
tates were suspended in 150 μΐ drug solution, i. e. a vol-
ume six times larger than in the inhibition experiments.
The dilution of the drug solutions by the small volume
of the precipitates and phosphate-buffered saline trapped
therein can therefore be ignored.
As controls for the albumin-binding experiments, the
same drugs (see fig. 1) were used for studies on the
immunoreaction between human γ-globulin and the ho-
mologous anti-y-globulin antibody. When the γ-globulin
solution was incubated with the drugs first and the ho-
mologous antibody added thereafter, some inhibitory ef-
fects were observed (fig. 2). These effects were quite
unexpected since none of the antirheumatic drugs under
investigation here is known to be bound to human γ-
globulin. However, when the human γ-globulin was pre-
cipitated with the homologous antibody first, followed
by incubation with anti-rheumatic drugs, the disrupting
effect was negligible. This suggests that the antigen was
enveloped so tightly by the homologous antibody that
the drugs no longer had access to the drug-binding sites
or to the immunological epitopes or paratopes of either
the antigen or the antibody, or both.
Discussion
The reversible, non-specific binding of numerous sub-
stances, e. g. drugs, hormones or dye-stuffs, to human
serum albumin or other plasma proteins was hitherto re-
garded as a unique phenomenon with some significance
for the passive (9) transport of such substances from the
blood stream into the organs, and vice versa. The present
study shows, however, that some non-sjpecific drug
binding sites of human serum albumin are identical with
immunologically specific epitopes and paratopes. The
inhibition by antirheumatics of antigen-antibody reac-
tions apparently is not confined to albumin-anti-albumin
precipitation, but also includes inhibition of γ-globulin-
anti^-globulin precipitation. In contrast to these find-
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Fig. 1 Inhibiting and disrupting effects of some antirheumatic
drugs on immunoprecipitation of human serum albumin.
Antigen: Mixture of 96% high purity grade human serum albumin
and 4% 125I-labelled human serum albumin, as indicator; 45 μg of
this mixture in 200 μΐ buffer (human serum albumin = 3.4 μηιοΐ/ΐ)
was placed in each centrifuge tube. Antibody: Anti-human serum
albumin serum pool from rabbits, #2/93. Each immunoprecipitate
contained 66—70% of 45 μg human serum albumin (= 460 pmol).
After immunoprecipitation, the blanks without drugs contained
31.5 μg human serum albumin each.
T, -L = standard deviation.
ίο1 ioz
Mol drug/Mol human serum albumin In the Immunoprecipitate added
a) Drugs in 25 μΐ phosphate-buffered saline added to human serum
albumin prior to addition of antibody,
b) human serum albumin precipitated with antibody first, followed
by addition of 150 μΐ of drug solution in phosphate-buffered saline
to washed precipitates. At the same drug molarities as in (a), the
absolute amounts of drugs were approximately six times greater in






ings on inhibitory effects, the disruption of preformed
antigen-antibody precipitates seems essentially to be re-
stricted to albumin-antialbumin precipitates. Thus, the
bonds involved in drug adsorption are not specifically
directed to drug-binding, but can also participate in im-
munological reactions.
Some antirheumatics other than those shown in figure 1
and 2 also disrupted immunoprecipitates or inhibited the
antigen-antibody reaction, though more weakly, e. g., so^
diurn salicylate, Aspirin® lysinate, indomethacin, piroxi-
cam and chloroquine. Several non-antirheumatic drugs
such as glibenclamid, promethazin, sodium oleate and
potassium sorbate manifested similar activities.
Our findings using a radioimrnunological technique
cannot be directly compared with the data of Rehse &
Fiedler (8) who used ultrafiltration. Nevertheless, there
is a striking parallel between the rank sequence order
of the albumin binding values of Rehse & Fiedler and
our results of immun -inhibition. For instance, these
authors found particularly powerful competition values
for diclofenac, ibuprofen, indomethacin and mofebuta-
zone, whereas salicylic acid was less powerful. Com-
mon to both methods, however, are the high coeffi-
cients of variation for most drugs.
For a more direct comparison of our data with those of
Rehse & Fiedler it would be necessary to calculate the
apparent dissociation coefficients for both inhibition and
disruption of the immunological bonds by the drugs.
This will be the subject of future communications. It
remains to be seen whether apparent coefficients ob-
tained by entirely different methods can be directly com-
pared.
As some preliminary experiments have shown, poly-






Mol drug/Mol human IgG added
Fig. 2 Control experiments: Inhibitory effects of some antirheu-
matic drugs on immunoprecipitation of human serum γ-globulins.
Antigen: 125I-labelled human IgG, 1.0 g/1 (96% purified human IgG
+ 4% 125I-labelled human IgG) in phosphate-buffered saline; 20 μΐ
per centrifuge tube. Antibody: Anti-human IgG pool from rabbits»
#1/93, 7 g/1. Each immunoprecipitate contained 47—49% of the
added 20 μg (418 μηιοΐ/l) human IgG. After immunoprecipitation,
the blank precipitates without drugs contained 10 μg each of hu-
man IgG. Drugs were added in 150 μΐ prior to addition of antibody.
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lead to somewhat different results. It seems therefore
advisable, for future investigations, to collect large pools
of antisera from different rabbits rather than to use mo-
noclonal antibodies, since the latter may not have all
desired paratopes. On the other hand, the results ob-
tained with monoclonal antibodies would probably be
more reproducible.
At present, it is not clear whether the inhibitory or dis-
rupting effects of drugs are associated with the therapeu-
tic efficacy or with undesirable side effects. It might be
speculated that the drugs investigated so far might also
inhibit immunoreactions or even disrupt immuno-com-
plexes in vivo. This would be of importance not only
with regard to possible impairment of immunological
diagnostic methods, but also in the therapy of immuno-
logically conditioned diseases. This class of diseases in-
cludes, e. g. autoimmune diseases, allergic disorders and
probably also Alzheimer's disease (11, 12) in which ben-
eficial effects of antirheumatic drugs such as indometha-
cin have been recently described.
However, some substances not used as drugs also pos-
sess inhibitory and disruptive properties, e. g. bromophe-
nol blue, sodium oleate, potassium sorbate, or HEPES
buffer pH 7. It may be that these substances belong to a
class of "chaotropic" compounds (13) that cause inexpli-
cable epiphenomena. Most antirheumatic drugs, how-
ever, do not possess such chaotropic properties. In any
case, use of the novel simple immunological method de-
scribed here may generate new information on the prop-
erties and chemical structure of drugs and other sub-
stances, and contribute to our knowledge of immuno-
chemical bonds.
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